Healthcasts Media’s Post

Nice slide deck. Very neat and simple way of explaining IO therapy. Power of great scientific communication. 

BMS Breaks New Ground in Liver Cancer Treatment: How AskMED.ai Tracks Emerging Trends in hepatocellular carcinoma https://askmed.ai/ #HealthcareInnovation #MedicalResearch #DataAnalytics #LiverCancer #Pharma #AskMEDai #HealthcareTechnology #PatientCare #MedicalInsights #HealthData

💡I made this carousel to provide information about the recently approved subcutaneous injection option for patients receiving atezolizumab as part of their cancer treatment. ⚫ #atezolizumab is a #drug used in #immunotherapy for certain #cancers ⚫ Atezolizumab is administered intravenously every 2-4 weeks, which can take up to 1 hour per patient ⚫ #NHS England will offer a 7 minute atezolizumab subcutaneous #injection option to eligible cancer patients - this injection could cut atezolizumab administration time by 75% per visit #cancer #cancertreatment #oncology #medicaleducation #medicalwriting #medicine #drugdelivery #clinical #drugs #pharmaindustry #health #science #sciencecommunication #scicomm #scicomms #healthcommunication #medcomms

Our unique approach to #cancer treatment with our proprietary compound, #LB100, has shown to enhance the efficacy of both chemotherapies and immunotherapies in pre-clinical models. Click to learn more about the science behind our PP2A-inhibitor. #inhibitors #immunotherapy #chemotherapy

Exciting news! The European Commission has approved Astellas Pharma Inc.'s XTANDITM (enzalutamide) for expanded prostate cancer treatment. This marks a significant milestone, offering a novel hormone therapy option for high-risk patients. Enzalutamide's approval is based on compelling results from the phase 3 Embark trial, showing significant reduction in cancer spread or death. Early treatment is crucial to prevent prostate cancer progression to metastasis. Astellas anticipates reflecting this approval's impact in its financial forecast, highlighting its significance for patients and the company. #FinancialImpact #MedicalAdvancement #ProstateCancer #Astellas #MedicalBreakthrough #EarlyDetection #CancerAwareness #ClinicalTrial #ResearchResults #ClynicoConsulting #CRO link to article: https://lnkd.in/ef5F8cCV

In Mexico, access to PSMA PET in public health systems is limited, leading to long waiting times or additional costs for the patient. At INCan México we have created a strategy to perform 99mTc PSMA SPECT/CT in patients with high-risk and very high-risk prostate cancer. This radiopharmaceutical in these clinical scenarios and using the infrastructure appropriately allows the identification of lesions up to 4mm #molecularimaging #nuclearmericine #INCan #symbiaT6

Blueprint Medicines' BLU-222 is gaining traction in oncology as a promising CDK2 inhibitor, particularly in HR+/HER2- breast cancer and other malignancies where CDK2 dysregulation is a major factor. The lifting of the partial clinical hold by the US FDA is a big step forward, suggesting that the safety concerns about BLU-222 have been appropriately addressed. The decision to pursue a partnership for BLU-222 in HR+/HER2- breast cancer exemplifies Blueprint Medicines' strategic approach of leveraging external expertise and resources to enhance the potential of its therapeutic concepts. However, the competitive landscape in the CDK2 inhibitor space presents a challenge, as several other companies are also advancing their candidates targeting this pathway.  According to DelveInsight, the total number of incident cases of HR+/HER2– breast cancer in the United States was 208,000 in the US. Access Unmatched Expert Insights and Comprehensive Analysis with DelveInsight Business Research LLP's American Society of Clinical Oncology (ASCO) 2024 Exclusive Coverage @ https://lnkd.in/diAwB5bU #asco24 #asco #ascoconference #BlueprintMedicines #BLU222 #CDK2Inhibitor #HRPositiveHER2Negative #BreastCancerTreatment #OncologyAdvances #FDAUpdate #ClinicalHoldLifted #CancerTherapy #StrategicPartnership #TherapeuticPotential #CompetitiveLandscape #CDK2Dysregulation #Malignancies #DelveInsight #BreastCancerIncidence #USHealthcare #CancerTreatmentOptions #InnovativeOncology #MedicalResearch #ClinicalTrials #PharmaceuticalDevelopment

The surge in cancer instances highlights the crucial role radiotheranostics plays in transforming global healthcare.   Per The Business Research Company’s Radiotheranostics Global Market Report 2023, Cancer Research UK reported 18 million new cancer cases, with projections foreseeing a staggering 54.9% increase by 2040, reaching 28 million cases annually.   Understand how radiotheranostics medicines stand at the forefront, offering the promise of personalized treatment through diagnostic and therapeutic radionuclide probes.   Explore our comprehensive report for an in-depth analysis radiotheranostics market: https://lnkd.in/dJP5P3Vu . . . #radiotheranostics #radiopharmaceuticals #targetedradiotreatmen #cancerresearch #tbrc #thebusinessresearchcompany #marketresearch #marketintelligence

Did you know that Mtech Access have a 100% success rate in UK health technology assessment (HTA) submissions in oncology? Email info@mtechaccess.co.uk to book a no obligation consultation meeting with our team. Learn more about how we can support your HTA submission at: https://lnkd.in/ep4xGxSd #HTA #marketaccess #oncology #pharma #medicines #cancer